# Safety and Efficacy of NK510 to Treat NSCLC

> **NCT06097962** · EARLY_PHASE1 · RECRUITING · sponsor: **Base Therapeutics (Shanghai) Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** NK510
- **DRUG:** Tislelizumab，atezolizumab or sugemalimab
- **DRUG:** NK510
- **DRUG:** systemic therapy as selected by the investigator

## Key facts

- **NCT ID:** NCT06097962
- **Lead sponsor:** Base Therapeutics (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06097962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06097962, "Safety and Efficacy of NK510 to Treat NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06097962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*